Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Trade Desk Inc (TTD) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Trade Desk IncTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Trade Desk Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.89 (market cap $29.60B), while Trade Desk Inc trades at $13.33 (market cap $6.37B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.6× Trade Desk Inc's market cap. Which is the better fit depends on your goals.

ALNYTTD
Market Cap
$29.60B$6.37B
Sector
HealthTechnology
52-Week High
$491.22$55.36
52-Week Low
$205.48$13.39
Enterprise Value
$27.56B$5.32B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.

The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.

Trade Desk Inc

The Trade Desk (TTD) stock trades at $13.39, down 2.97% today and near 52-week lows after a sharp 90% decline from its 2024 peak. Recent Q2 2026 earnings missed expectations with 3% revenue growth and weak Q3 guidance, triggering analyst downgrades. Technical indicators are bearish, with support at $12. The company maintains strong profitability margins but faces growth deceleration and competitive pressures in digital advertising.

Outlook remains cautious due to execution gaps and macroeconomic headwinds. While valuations appear reasonable with a P/E of 16.14, near-term risks from revenue declines and advertiser pullbacks outweigh potential upside. Investors should monitor Q3 earnings for signs of stabilization before considering entry.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Trade Desk Inc

The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.

Read more on TTD